Ignota Labs

Labs Rescuing Promising but Failed Drugs, Breathing New Life into Abandoned Projects and Bringing New Hope to Patients. Over half of clinical trials fail due to safety issues, resulting in a staggering $400 billion loss annually and delaying life-saving treatments for patients. Our proprietary platform SAFEPATH utilizes cutting-edge deep learning to address these challenges by uncovering the mechanisms behind drug toxicity. Unlike traditional safety assessments that only identify where problems occur, our AI platform SAFEPATH integrates cheminformatics, bioinformatics, and multimodal data analysis to explain why and how safety issues arise, providing actionable insights to improve or repurpose drug candidates. Ignota Labs is building a robust pipeline to bring safer drugs to market faster, collaborating on and co-developing assets that might otherwise fail, and accelerating the delivery of critical therapies to patients in need.